NICE recommends Eliquis

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Eliquis apixaban from Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF) with one or more risk factors. The European Commission approved Eliquis for the indication in November. NICE said Eliquis is cost-effective compared to warfarin and estimated the most plausible incremental cost-effectiveness ratio (ICER) for the direct Factor Xa inhibitor to be less than L20,000 ($31,750) per quality-adjusted life year (QALY). Final guidance is expected next month. ...